A5059789645- Retinal Imaging and Analysis
- Retinal Diseases and Treatments
- Corneal Surgery and Treatments
- Glaucoma and retinal disorders
- Neurological Disease Mechanisms and Treatments
- Retinal Development and Disorders
- Atherosclerosis and Cardiovascular Diseases
- Intraocular Surgery and Lenses
- Retinal and Macular Surgery
Hospital Universitario Virgen de las Nieves
2021
Roche (United States)
2018-2019
<h3>Importance</h3> Geographic atrophy (GA) secondary to age-related macular degeneration is a leading cause of visual disability in older individuals. A phase 2 trial suggested that lampalizumab, selective complement factor D inhibitor, reduced the rate GA enlargement, warranting 3 trials. <h3>Objective</h3> To assess safety and efficacy lampalizumab vs sham procedure on enlargement GA. <h3>Design, Setting, Participants</h3> Two identically designed double-masked, randomized,...
PurposeTo better characterize visual function decline and geographic atrophy (GA) progression secondary to age-related macular degeneration (AMD).DesignProxima A (NCT02479386)/Proxima B (NCT02399072) were global, prospective, noninterventional, observational clinical trials.ParticipantsEligible patients aged ≥50 years. Patients in Proxima had bilateral GA without choroidal neovascularization (CNV) either eye (N = 295). CNV the study CNV±GA fellow (fellow cohort, n 168) or eye, no CNV/GA...
Intraocular pressure (IOP) elevations of clinical relevance have been observed after the commonly used 0.05-mL volume for intravitreous injections. However, more recently approved agents involve volumes from 0.07 to 0.1 mL. It is not well established whether repeated 0.1-mL injections may result in IOP-related complications.